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Abstract 
Background. A role of an estrogen-regulated, autocrine motogenic factor was assumed to be a 
major biological role of trefoil factor 1 (TFF1) in breast cancer. TFF1 is regarded as a predictive 
factor for positive response to endocrine therapy in breast cancer patients. The aim of our study 
was to examine TFF1 level distribution in breast carcinomas in order to distinguish estro-
gen-independent from estrogen-dependent TFF1 expression and to evaluate clinical usefulness of 
TFF1 status in early breast cancer during the first 3 years of follow-up.  
Methods. The study included 226 patients with primary operable invasive early breast carcinomas 
for whom an equal, a 3-year follow-up was conducted. TFF1 levels as well as estrogen receptor 
(ER) and progesterone receptor (PR) levels were measured in cytosolic extracts of tumor samples 
by immunoradiometric assay or by use of classical biochemical method, respectively. 
Non-parametric statistical tests were applied for data analyses. 
Results. Statistical analysis revealed that TFF1 levels were signiﬁcantly higher in premenopausal 
patients (p=0.02), or in tumors with: lower histological grade (p<0.001), positive ER or PR status 
(p<0.001, in both cases). On the basis of TFF1 level distribution between ER-negative and 
ER-positive postmenopausal patients with tumors of different histological grade, 14 ng/mg was set 
as the cut-off value to distinguish estrogen-independent from estrogen-dependent TFF1 expres-
sion in breast cancer. Depending on menopausal and PR status, positive TFF1 status identified 
patients at opposite risk for relapse among ER-positive patients with grade II tumors. Among ER- 
and PR-positive premenopausal patients with grade II tumors, TFF1 status alone identified patients 
at opposite risk for relapse.  
Conclusions. Determination of TFF1 status might identify patients at different risk for relapse and 
help in making decision on administering adjuvant therapy for early breast cancer patients during 
the first 3 years of follow-up. 
Key words: trefoil factor 1; cut-off value, disease-free interval; early breast carcinoma; early fol-
low-up. 
Introduction 
Trefoil factors (TFFs) represent a family of small 
peptides (6-10 kDa) characterized by a common se-
quence, consisting of 42-43 amino-acids and highly 
conserved in mammals [1]. Intramolecular disulphide 
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bonds within the sequence cause the formation of the 
characteristic three-loop structure, called the trefoil 
domain [1, 2], making TFFs stable molecules that are 
relatively resistant to proteases. Three mammalian 
trefoil peptides are known: TFF1 (formerly pS2) and 
TFF3 (intestinal trefoil peptide) contain one while 
TFF2 (spasmolytic polypeptide) contains two trefoil 
domains [3]. Trefoil factor 1 is a small cysteine-rich 
acidic peptide consisting of 60 amino acids [1]. In 
normal human tissues, TFF1 is predominantly ex-
pressed in the gastrointestinal tract [4] and, although 
its biological function is not clarified, it seems to have 
an important role in preserving the mucosa of the 
gastrointestinal tract [5]. In malignant tissue, TFF1 
was initially found in breast cancer [6], but it has also 
been detected in several other carcinomas, such as 
stomach, pancreas, large intestine, endometrium, 
ovary, uterus, bladder, and prostate [7-10].  
Hormones (estradiol [11]), growth factors such 
as insulin-like growth factor I (IGF-I), IGF-II, epider-
mal growth factor (EGF) or transforming growth fac-
tor (TGF) [11-13], phorbol esters [11, 14], plasminogen 
activator and Fos and Jun oncoproteins [11] have been 
reported to regulate the expression of the TFF1 
through the activation of the gene promoter contain-
ing an estrogen-response element (ERE) and a 
TPA-response element (TRE) [15]. The peptide was 
found to be overexpressed in approximately 50 % of 
primary breast carcinomas [16], mainly estrogen re-
ceptor alpha-positive (ERα+) ones. It has been 
demonstrated that estrogen stimulation of an estro-
gen-dependent breast cancer cell line induce signifi-
cant (up to 100-fold) increase of TFF1 mRNA as well 
as an increase of protein level [6].  
Despite numerous studies, the biological func-
tion of TFF1 in breast cancer is not yet clarified. Con-
sidering that low levels of TFF1 were shown to be 
characteristic for normal breast tissue, it has been 
proposed that overexpression of the peptide in breast 
cancer indicates its adverse function, possible as an 
oncogene. Early studies indicated that TFF1 might be 
a mitogen but they failed to demonstrate such bio-
logical function. Recent studies provided evidence 
regarding the possible role of TFF1 in breast cancer 
contributing to tumor aggressiveness. TFF1 was 
found to stimulate cell proliferation both in vitro and 
in models [17]. It has been reported that TFF1, in-
duced by estrogen, stimulates migration of breast 
cancer cells [18, 19]. Moreover, TFF1 dimer was 
shown to be more effective than TFF1 monomer in 
stimulation of breast cancer cell motility [19], possible 
due to its interaction with a putative cell surface re-
ceptor that has not been yet identified. A role of an 
estrogen-regulated, autocrine motogenic factor was 
assumed to be a major biological role of TFF1 in breast 
cancer. 
The finding that TFF1 overexpression has been 
detected in approximately 50 % of breast carcinomas 
[7], while only low levels of the peptide have been 
found in normal breast tissue [16] provided a ra-
tionale for numerous studies evaluating the potential 
clinical significance of TFF1 in breast cancer. The 
protein is not only regarded as an indicator of the 
intact ER signaling pathway [20, 21], it is considered 
to be a predictive factor for positive response to en-
docrine therapy in breast cancer patients [21-26]. 
Furthermore, some studies suggested that TFF1 ex-
pression might be useful in identifying the subgroup 
of ER-positive breast cancer patients being more re-
sponsive to aromatase inhibitors (AI) than to Tamox-
ifen [27]. Most studies reported on association be-
tween TFF1 expression in breast cancer and a favora-
ble prognosis [16, 21, 25, 28-32] while some studies 
failed to confirm such correlation [33].  
In our study, a significant difference in TFF1 
levels was found in relation to either menopausal 
status, histological grade, estrogen receptor (ER) sta-
tus or progesterone receptor (PR) status. The first aim 
of our study was to determine a biologically-related 
cut-off value for TFF1 expression that would allow us 
to distinguish between estrogen-dependent and es-
trogen-independent TFF1 expression in breast cancer. 
On the basis of TFF1 level distribution in both 
premenopausal and postmenopausal patients bearing 
ER-positive and ER-negative tumors (regardless of 
histological grade), a concentration of 14 ng/mg of 
TFF1 was established as a cut-off value for TFF1 ex-
pression in breast cancer. The second aim of our study 
was to evaluate a potential clinical relevance of TFF1 
in breast cancer, on the basis of the established cut-off 
value. Therefore, we analyzed disease free-interval 
(DFI) probabilities in relation to TFF1 status. TFF1 
status allowed us to discriminate between patients 
with high versus low risk for development of distant 
metastases during a 3-year follow-up after the sur-
gery. 
Methods 
This retrospective study included tumor samples 
from 226 consecutive female patients with clinical 
stage I or stage II breast cancer. After the surgery, 
primary operable invasive early breast carcinomas 
were histologically verified for all patients in the 
study. In the adjuvant setting of these patients, treated 
at the Institute for Oncology and Radiology of Serbia 
between 2002 and 2005, chemotherapy was given to 
64 patients (32 %), the same number of patients re-
ceived hormonotherapy, both types of systemic ther-
apy were administered to 32 patients (16 %) while 41 
patients (20 %) received no adjuvant therapy. Histo-
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logical specimens were reviewed and then classified 
according to the criteria of the International Union 
Against Cancer for TN stages [34] and according to 
the criteria for histological type [35] and grade [36]. 
Patients were between 24 and 78 years old (median, 56 
years). Patients were considered to be postmenopau-
sal if menstruation ceased for at least six months, 
otherwise they were considered as premenopausal. 
Patients’ and tumor characteristics are presented in 
Table 1.  
 
Table 1. Cytosolic TFF1levels in 226 breast carcinomas: corre-
lation with different clinico-pathological parameters. 
Patient and tumor char-
acteristics 
n % TFF1 (ng/mg) p 
value* Range Median 
Total 226 100 1.5-135.8 9  
Age (years)      
<45 39 17.2 2-82.9 17.7 NS 
45-59 96 42.5 1.5-124.1 7.9 
>59 91 40.3 1.8-135.8 9.4 
Menopausal status      
Premenopausal 77 34.1 2-124.1 13.6 0.02 
Postmenopausal 144 63.7 1.5-135.8 8 
Unknown 5 2.2    
Nodal status      
pN0 92 40.7 1.5-135.8 7.4 NS 
pN+ 112 49.6 2-124.1 11.2 
Unknown 22 9.7 1.6-58.1   
Tumor size      
pT1 100 44.2 1.5-135.8 10.6 NS 
pT2 114 50.4 1.9-124.6 8.4 
pT3 8 3.6 2.2-19.4 13.2 
Unknown 4 1.8    
Histological grade      
I 33 14.6 1.9-56.2 7.3 <0.001 
II 146 64.6 1.6-124.6 12.1 
III 43 19 1.5-137.4 3.1 
Unknown 4 1.8    
Histological type      
IDC 112 49.6 1.5-137.4 6.4 NS 
ILC 80 35.4 2-124.1 12 
Other 34 15 1.6-55.4 13.7 
ER status      
ER+ 153 67.7 1.6-137.4 15.9 <0.001 
ER- 73 32.3 1.5-66 3.7 
PR status      
PR+ 102 45.1 1.6-137.4 15.4 <0.001 
PR- 124 54.9 1.5-124.6 5.2 
* Mann-Whitney or Kruskal-Wallis test. 
 
Patients’ follow-up was conducted every three 
months for the first two years and every six months 
during the third year. The recurrence of the disease 
was set as an end-point in our study because it is 
clinically useful in regard to metastatic disease pro-
gression. Disease-free interval was defined as time 
from the initial diagnosis to the emergence of distant 
metastases. The follow-up data were available for 201 
patients and these patients were included in the sur-
vival analysis. Forty-three (21.4 %) patients developed 
distant metastases during a 3-year follow-up. The 
study was approved by the Ethics Committee of the 
Institute of Oncology and Radiology of Serbia and the 
patients provided their informed consent before en-
tering the study. 
Estrogen receptor and progesterone receptor 
levels in cytosol extracts of tumor samples were 
measured by using the classical biochemical method 
as recommended by the European Organisation for 
Research and Treatment of Cancer (EORTC) [37]. The 
intra-laboratory quality assessment of the steroid 
hormone receptor levels was performed periodically 
following the EORTC recommendation [38]. The 
cut-off value for the quantitative classiﬁcation of pos-
itive receptor status was 10 fmol/mg for ER and 20 
fmol/mg for PR [39]. TFF1 levels were assayed in 
tumor cytosols obtained for routine ER and PR de-
termination and were measured by using a sol-
id-phase radioimmunoassay (ELSA-pS2 Cis Bioin-
ternational, Gif-Sur-Yvet, France). The assay was 
performed according to the manufacturer’s instruc-
tions. Concentration of TFF1 was expressed in ng/mg 
protein. Cytosol protein concentration was deter-
mined by the Lowry method [40].  
The non-parametric statistical methods were 
applied for data analyses. The distribution of TFF1 
levels between the subgroups of patients was assessed 
using Mann-Whitney or Kruskal-Wallis test. Spear-
man’s rank correlation test was used to assess the 
correlation between two variables. Survival curves for 
DFI were estimated according to the method of 
Kaplan and Meier. The log-rank test was used to 
compare survival functions. The distribution of dif-
ferent therapies between subgroups of patients was 
evaluated by Chi-squared test. A limit for significance 
was set at p<0.05. 
Results 
The distribution of TFF1 levels within the an-
alyzed group of 226 breast carcinomas was statisti-
cally different from the normal distribution (Kol-
mogorov-Smirnov test, p<0.001) and it is presented 
in Figure 1. A wide range of TFF1 levels was de-
tected in breast carcinomas and protein levels varied 
from 1.5 to 135.8 ng/mg protein, with a median 
value of 9 ng/mg protein. The distribution of TFF1 
levels in relation to tumor-host (age, menopausal 
status) and tumor parameters (axillary node status, 
tumor size, histological grade, histological type, ER 
and PR status) is shown in Table 1. Statistical analy-
sis revealed that TFF1 levels were significantly 
higher in premenopausal than in postmenopausal 
patients (p=0.02) as well as in patients bearing his-
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tological grade I or II tumors compared to those 
bearing histological grade III tumors (p<0.001). In 
addition, ER-positive (ER+) or PR-positive (PR+) 
tumors were characterized with higher TFF1 levels in 
comparison to ER-negative (ER-) or PR-negative 
(PR-) tumors, respectively (p<0.001 in both cases). 
The last result may be expected, considering a statis-
tically significant correlation between TFF1 and ei-
ther ER or PR levels in analyzed samples of breast 
carcinoma (r=0.295, p<0.001 and r=0.254, p<0.001, 
respectively). Regardless of significant differences in 
TFF1 levels between the indicated groups of patients, 
the ranges of peptide levels between corresponding 
groups were comparable (as shown in Table 1) and 
we were unable, on the basis of these results, to de-
fine biologically-related cut-off value for TFF1 ex-
pression in breast carcinomas.  
 
Figure 1. Frequencies of cytosolic TFF1 levels. Frequencies of cytosolic 
TFF1 levels in 226 breast carcinomas, at intervals of 10/20 ng/mg. 
 
 
In an effort to discriminate estrogen- 
independent from estrogen-dependent TFF1 expres-
sion, the distribution of TFF1 levels was, further, an-
alyzed between the groups of patients defined by 
combining menopausal status, histological grade, ER 
status and PR status. Figure 2 shows the distribution 
of TFF1 levels in ER-positive and ER-negative post-
menopausal patients bearing tumors of different his-
tological grade. Among postmenopausal patients, 
those with ER-negative status had significantly lower 
TFF1 levels in comparison to those with ER-positive 
status, irrespective of tumor histological grade 
(p=0.04, p<0.001 and p<0.05 for histological grade I, II 
and III, respectively). On the other hand, the ranges of 
TFF1 levels of postmenopausal patients with tumors 
of different ER status (ER+ vs. ER-) were not compa-
rable within the same histological grade of tumor. 
Since the highest TFF1 levels in ER-negative tumors of 
postmenopausal patients were similar across tumors 
of different histological grade (12.3, 13.9 and 9.6 for 
histological grades I, II and III, respectively), we es-
tablished 14 ng/mg as the cut-off value to discrimi-
nate between estrogen-dependent and estro-
gen-independent TFF1 expression in breast cancer. 
Accordingly, we were able to define TFF1 status as a 
positive (TFF1+) or a negative one (TFF1-), depending 
on whether TFF1 levels in tumors were higher or 
lower than the cut-off value.  
 
 
Figure 2. Distribution of TFF1 levels. Distribution of TFF1 levels in ER-positive and ER-negative postmenopausal patients bearing tumors of different 
histological grade. 
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Statistical analysis showed that TFF1 status alone 
did not show a significant association with DFI 
probabilities during the first 3 years of patients’ fol-
low-up (data not shown). Therefore, we compared 
DFI probabilities between groups of patients defined 
by different clinico-pathological parameters, focus-
ing to parameters that appeared to affect TFF1 level 
distribution in breast cancer.  
Analysis of premenopausal patients bearing 
ER-positive and PR-positive tumors of histological 
grade II revealed a statistically significant difference 
in DFI probabilities between patients with positive- 
and negative TFF1 status, where those with positive 
TFF1 status had significantly lower DFI probabilities 
(p<0.05, Figure 3). In addition, postmenopausal and 
PR status were found to affect DFI probabilities of 
TFF1-positive patients with ER-positive tumors of 
grade II in such a way that: a) among patients with 
positive PR status, premenopausal patients had sig-
nificantly lower DFI probabilities in comparison to 
postmenopausal ones (p=0.009, Figure 4) and b) 
among postmenopausal patients, those with nega-
tive PR status had significantly lower DFI probabili-
ties in comparison to those with positive PR status 
(p=0.04, Figure 5). By use of Chi-squared test, analy-
sis revealed no difference in distribution of adjuvant 
systemic therapies among analyzed subgroups of 
patients during the first 3 years of follow-up (data 
not shown). 
 
Figure 3. Probability of disease-free interval, stratified according to negative or positive TFF1 status. Probability of disease-free interval for ER-positive and 
PR-positive premenopausal breast cancer patients bearing tumors of histological grade II, stratified according to negative (TFF1-) or positive (TFF1+) TFF1 
status. The number of patients with distant metastases/total number of patients is indicated in brackets. The solid line indicates negative and the dashed line 
indicates positive TFF1 status. Pre: Premenopausal status. 
 
Figure 4. Probability of disease-free interval, stratified according to pre- or post-menopausal status. Probability of disease-free interval for ER-positive, 
PR-positive and TFF1-positive breast cancer patients bearing tumors of histological grade II, stratified according to premenopausal (Pre) or postmenopausal 
(Post) status. The number of patients with distant metastases/total number of patients is indicated in brackets. The solid line indicates postmenopausal and 
the dashed line indicates premenopausal patients. Post: Postmenopausal status. 
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Figure 5. Probability of disease-free interval, stratified according to negative or positive PR status. Probability of disease-free interval for ER-positive and 
TFF1-positive postmenopausal breast cancer patients bearing tumors of histological grade II, stratified according to PR-negative (PR-) or PR-positive (PR+) 
status. The number of patients with distant metastases/total number of patients is indicated in brackets. The solid line indicates positive and the dashed line 
indicates negative PR status. 
 
Discussion 
The distribution of TFF1 levels in our study 
(Figure 1), in addition to a wide range of protein lev-
els, implies that breast cancer is a heterogeneous dis-
ease. Our finding that high TFF1 levels were related to 
premenopausal patients is in accordance with the 
findings of other studies [21, 41], although some op-
posite findings were also reported [32]. Considering 
that middle-aged group (45-59 years old) consisted of 
both premenopausal and postmenopausal patients 
while all patients younger than 45 were premeno-
pausal and all patients older than 59 were postmen-
opausal in our study, age of the patients was not an-
alyzed as a continuous variable, but stratified into 
three age subgroups. Although such stratification 
might be a possible reason why a significant differ-
ence in TFF1 levels was not found in relation to age of 
patients in our study, our results confirm some liter-
ature data showing that expression of some 
ER-inducible proteins, including TFF1, are not signif-
icantly related with the age at diagnosis [42, 43] . Our 
results also confirm the results of some previous 
studies reporting that TFF1 expression is negatively 
associated with histological grade of tumor [21, 30, 32, 
44] while positively associated with ER [21, 29, 45] or 
PR positivity [21, 30, 46]. Considering that a negative 
correlation between histological grade and ER posi-
tivity of tumors has been demonstrated previously 
[47], results of our study are not surprising. However, 
not all the studies have demonstrated such association 
between TFF1 expression and ER [48] or PR positivity 
[49] or histological grade [29, 32] of tumor. The ma-
jority of studies, including ours, failed to demonstrate 
any association between TFF1 and lymph node in-
volvement or tumor size [21, 30, 32, 50] which may 
indicate that TFF1 expression is not related to the 
stage of tumor development. However, a negative 
association between TFF1 expression and lymph node 
involvement [27, 44] or tumor size [44] has been re-
ported in some studies.  
The choice of an optimal TFF1 cut-off value may 
be essential for assessing a potential clinical relevance 
of TFF1 in breast cancer as it may lead to a better 
stratiﬁcation of breast cancer patients’ subgroups. The 
result of such stratification should contribute to the 
improvement of patients’ treatment in a way to apply 
treatment at an earlier stage of the disease or to avoid 
unnecessary risk for patients who will not beneﬁt of 
an additional treatment.  
In many studies, various statistically-related 
values were used as cut-off values in order to dis-
criminate between TFF1-positive and TFF1-negative 
patients that might be at different (low/high) risk for 
developing distant metastases after primary therapy. 
In our study, we applied a different approach aiming 
to find a biologically-related cut-off value that would 
allow us to discriminate between estrogen-dependent 
and estrogen-independent TFF1 expression in breast 
carcinoma. As we were unable to determine such a 
cut-off value just on the basis of TFF1 level distribu-
tion in relation to either menopausal status, histolog-
ical grade, ER status or PR status, we performed ad-
ditional analysis of the distribution of TFF1 levels in 
relation to ER and/or PR status among patients 
bearing tumors of different histological grade. The 
additional analysis was performed both within the 
group of postmenopausal (Figure 2) and within the 
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group of premenopausal patients (data not shown). 
Within the group of postmenopausal patients, the 
analyses of TFF1 levels revealed that: 
• ER-negative patients had significantly lower 
protein levels in comparison to ER-positive ones, 
regardless of histological grade of tumor, 
• the range of TFF1 levels for ER-negative patients 
was not comparable with the one corresponding 
to ER-positive patients, regardless of histological 
grade of tumor, 
• the highest TFF1 level of ER-negative patients 
was less than 14 ng/mg protein. 
Among premenopausal patients, however, TFF1 
levels in ER-negative tumors were neither signifi-
cantly different from the corresponding levels in 
ER-positive tumors nor lower than 14 ng/mg, within 
all three histological grades.  
It is well known that postmenopausal women 
have significantly lower estrogen levels in comparison 
to premenopausal ones. Nevertheless, these low es-
trogen levels in postmenopausal women are still able 
to induce estrogenic response in a way to stimulate 
TFF1 expression in breast cancer cells. In addition, 
TFF1 expression in breast cancer may also be induced 
by growth factors, such as IGF-I [15, 25], via signaling 
pathway that are related or not to ER, thus making it 
estrogen-independent. On the basis of our results, we 
assumed that TFF1 expression is predominantly reg-
ulated by growth factors in ER-negative tumors of 
postmenopausal patients while additionally regulated 
through indirect estrogen-dependent ER signaling 
pathways in ER-positive tumors of these patients [51]. 
We further assumed that indirect estrogen-dependent 
ER signaling pathways may dominantly regulate 
TFF1 transcription in ER-negative tumors of 
premenopausal patients while a classical, estro-
gen-dependent ER signaling pathway is supposed to 
be dominant in ER-positive tumors of these patients. 
Based on these assumptions, the highest TFF1 level in 
ER-negative tumors of postmenopausal patients was 
considered as a maximum of estrogen-independent 
TFF1 expression. A value of 14 ng/mg of protein was 
established as the cut-off value to distinguish between 
estrogen-dependent and estrogen-independent TFF1 
expression. Accordingly, patients with TFF1 levels 
lower or higher than the cut-off value were regarded 
as those with TFF1-positive or TFF1-negative status, 
respectively. 
It should be noted that PR levels were signifi-
cantly correlated to TFF1 levels in our study but they 
seem to have no effect on estrogen-(in)dependent 
TFF1 expression in breast carcinoma. It may be as-
sumed that PR and TFF1 participate in ER signaling in 
breast cancer not through common but distinct 
pathways. Some differences in clinico-pathological 
and biological characteristics between PR and TFF1 
have already been considered by other investigators 
hypothesizing that estrogen-independent signaling of 
TFF1 is different from the one of PR in 
post-menopausal women with ER-positive breast 
cancer [27]. A question arises on whether a similar 
difference in TFF1 and PR signaling pathways in 
breast cancer may be hypothesized in case of estro-
gen-dependent signaling of TFF1 and we believe it 
may be.  
Detection of low TFF1 expression in normal 
breast tissue and its high expression in majority of 
breast carcinomas has been the rationale for numer-
ous studies on the potential clinical value of TFF1 
expression in breast cancer [52]. Despite the increas-
ing amount of data on this subject, the findings are 
inconclusive. In many studies, especially in those us-
ing cytosol-based assay, a better prognosis was asso-
ciated with patients bearing TFF1-positive tumors. A 
favorable outcome was related to both disease-free 
and overall survival. Numerous studies also sug-
gested that TFF1 expression may be a predictive in-
dicator of positive response to endocrine therapy in 
ER-positive breast cancer patients and, moreover, an 
indicator of sensitivity to AI over Tamoxifen. TFF1 
expression has even been identified as an informative 
marker for the detection of micrometastases [53]. In 
several studies, however, the prognostic or predictive 
value of TFF1 expression in breast cancer has not been 
demonstrated [27,30]. 
Studies on the clinical value of TFF1 in breast 
cancer may differ among each other in many issues. 
Cohorts of patients, the length and end-points of fol-
low-up, methodologies used for determination of 
TFF1 expression, cut-off values for TFF1 positivity, 
etc. represent some of the variables that may affect the 
findings as well as the conclusions of such studies. 
The follow-up after the surgical therapy is not usually 
a predefined period of time and differences in pa-
tients’ follow-up exist within as well as among stud-
ies, even when the same end-points are considered. In 
order to avoid the possible adverse impact of the var-
ying follow-up, a requirement of an equal follow-up 
period (3 years) has been set up for all patients in-
cluded in the study.  
It has previously been reported that a clinical 
relevance of a biomarker may change in time follow-
ing the surgical treatment. Several studies reported on 
the potential of ER status as a prognostic indicator in 
the early follow-up (mostly 2-2.5 years after the sur-
gery), as its prognostic strength weakened over time 
[54, 55], while others reported on prognostic relevance 
of ER status in the late follow-up [56]. A time-varying 
effect of nodal status, tumor size and histological 
grade on prognosis of breast cancer patients has also 
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been reported by several studies [54, 57]. Considering 
potentially time-dependent clinical relevance of a 
biomarker, the choice of an optimal follow-up seems 
important in order to obtain a relevant evaluation of 
an indicator of the clinical outcome.  
The emergence of distant metastases in breast 
cancer has been shown to follow a double-peak pat-
tern with an early peak at about 2-3 years after sur-
gery and a late peak at about 5 years after surgery [55, 
58]. It has been proposed that the surgical therapy 
induce an increase of probability for the transition of 
non-dividing single cells to a state of avascular mi-
crometastases [59] and, further, to a phase of vascu-
larization and further growth [60], resulting eventu-
ally in an early peak. It is well known that, in terms of 
breast cancer-specific overall survival, the shorter the 
interval, the shorter the patient is expected to survive. 
Given the importance of the early follow-up and by 
considering a possible time-dependent clinical rele-
vance of a biomarker, it seemed reasonable to us to 
assess the potential clinical value of TFF1 in primary 
operable breast carcinoma during the first 3 years of 
follow-up. Such investigation was also based on our 
finding that no difference in DFI probabilities was 
found between groups of patients who were subjected 
to different modalities of adjuvant systemic therapy: 
no therapy vs. chemotherapy vs. hormonotherapy vs. 
chemo+hormonotherapy (data not shown). Our prin-
cipal aim was to eventually identify subgroups of 
primary operable breast carcinoma where TFF1 ex-
pression might help to discriminate between patients 
at low vs. high risk for development of distant me-
tastases in a 3-year follow-up after the surgery.  
Some previous studies have suggested that high 
expression of TFF1 is associated with breast carcino-
mas of a more benign course [27, 32, 44]. Our results 
are, partially, in contrast with such finding and sug-
gest a possible adverse effect of high levels of TFF1 in 
breast carcinoma (at least in some of its specific sub-
groups). It has been presumed that TFF1 might act as 
a mitogen but early studies failed to demonstrate such 
biological function. Numerous studies have reported 
on a role of TFF1 in stimulating the motility and in-
vasion of breast cancer cells [17, 19, 21]. By acting as a 
motogen, TFF1 was suggested to promote cell dis-
semination and development of metastases in breast 
cancer, two processes associated with more aggres-
sive tumor behavior.  
A positive role of TFF1 in breast cancer cell mi-
gration might provide a rationale for our result, 
showing a worse outcome for TFF1-positive 
premenopausal patients bearing ER-positive and 
PR-positive tumors of histological grade II, in com-
parison to these patients with negative TFF1 status 
(Figure 3). As previously mentioned, it may be as-
sumed that TFF1 exerts its function through a classical 
ER signaling pathway that might be predominant in 
tumors of premenopausal patients due to high levels 
of estrogen. Additional reason for a worse outcome of 
these TFF1-positive patients may be a potential role of 
TFF1 in proliferation of breast cancer cells since in-
creased levels of TFF1 have been demonstrated to 
stimulate this process in breast cancer [17]. A potential 
role of TFF1 in proliferation and/or migration of 
breast cancer cells might be further indicated by the 
result showing that none of these TFF1-negative pa-
tients developed distant metastases during a 3-year 
follow-up. This result indicates that TFF1 might sig-
nificantly affect migration and/or proliferation when 
its concentration is high enough, i.e. at levels higher 
than the cut-off value. 
Menopausal status seemed to be important in 
terms of clinical outcome among patients bearing 
ER+, PR+ and TFF1+ tumors of histological grade II. 
We found a significant difference in DFI probabilities 
between premenopausal and postmenopausal pa-
tients within the indicated phenotype where none of 
postmenopausal patients developed distant metasta-
ses during the first 3 years after the surgery (Figure 4). 
Our result concerning postmenopausal patients sug-
gests that the proliferation and/or migration of breast 
cancer cells in ER+, PR+ and TFF1+ tumors of grade II 
are either stimulated to a low extent or not stimulated 
at all by higher levels of TFF1. The reason for poten-
tially low/no stimulation of proliferation and/or mi-
gration of breast cancer cells might be due to TFF1 
signaling that is presumable not directly dependent 
on estrogen action in these tumors. It should be em-
phasized that patients with favorable course of the 
disease, as presented in Figures 3 and 4, have had 
higher DFI probability than pN0 patients, for whom 
DFI probability was 0.86, while patients with unfa-
vorable course of the disease have had lower DFI 
probability compared to pN+ patients, for whom DFI 
probability was 0.68. 
Estrogen-independent TFF1 signaling may be 
considered as responsible for a potential role of PR in 
suppressing tumor cell motility and/or proliferation 
in ER-positive, histological grade II tumors of post-
menopausal patients (Figure 5). Expression pathways 
of TFF1 and PR in breast cancer may be distinct as it 
was observed that growth factors, such as IGF-I, may 
increase TFF1 expression while decreasing PR levels, 
irrespective of ER levels [61]. However, the role of ER 
(ERα precisely) in the regulation of TFF1 expression 
can be overridden due to high levels of activating 
histone modifications in the genome. It has been re-
ported that accumulation of these modifications at 
TFF1 promoter may facilitate the binding of other 
transcription factors, rather than ER, that could con-
Int. J. Med. Sci. 2014, Vol. 11 
 
http://www.medsci.org 
671 
tribute to pathways responsible for the development 
of estrogen-independent breast tumors [62]. There-
fore, within the group of ER-positive, postmenopau-
sal patients bearing tumors of histological grade II, we 
supposed that growth factor-regulated TFF1 signaling 
pathways (dependent or not on ER) are dominant in 
PR-negative tumors. Considering the potential role of 
TFF1 in promoting cancer cell migration and prolif-
eration [19] [18], the cross-talk between TFF1 and PR 
signaling pathways may be assumed in case of 
TFF1-positive, postmenopausal patients bearing tu-
mors of histological grade II. It is possible that high 
levels of PR suppress tumor cell motility by prevent-
ing TFF1 dimerization as TFF1 dimer was shown to be 
more potent than TFF1 monomer in stimulating breast 
cancer cell migration [19]. High levels of PR might be 
also presumed to contribute somehow to a lower tu-
mor cell proliferation. Consequently, the motili-
ty/proliferation of tumor cells is probably less sup-
pressed in tumors of PR-negative patients. Some pre-
vious studies suggested that dual determination of 
TFF1 and PR may be unnecessary since estro-
gen-dependent tumors will express both proteins. 
Our results are in favor of simultaneous determina-
tion of these two proteins in, at least, ER-positive tu-
mors of histological grade II as their joint status might 
help to identify patients at opposite risk for devel-
opment of distant metastases during the first 3 years 
after the surgery. 
In regard with above mentioned results, it 
should be emphasized that analysis revealed a uni-
form distribution of modalities of adjuvant systemic 
therapies among analyzed subgroups of patients (data 
not shown). It is noteworthy that none of 14 
TFF1-positive postmenopausal patients (Figures 4 and 
5), in addition to none of 8 TFF1-negative premeno-
pausal patients (Figure 3), all bearing ER-positive and 
PR-positive tumors of histological grade II, developed 
distant metastases during the first 3 years of fol-
low-up. This finding suggests that adjuvant systemic 
therapy might be omitted in case of these patients. 
One could argue on numbers of patients analyzed in 
each subgroup with regard to DFI probabilities. Alt-
hough numbers are small in absolute terms, two facts 
should be taken into account when considering those 
numbers. Patients who were included in DFI analysis 
were supposed to meet several criteria simultane-
ously with respect to clinico-pathological features, i.e. 
patients were stratified according to both menopausal 
status, histological grade, ER status, PR status and 
TFF1 status. We believe this was quite a demanding 
prerequisite for the analysis, leading to small numbers 
of patients analyzed within each subgroup. One may 
assume that those numbers would be greater within a 
much larger group of patients (a thousand or several 
thousands of patients). Having in mind aforemen-
tioned, our viewpoint is that numbers of patients re-
lated to each subgroup within DFI analysis are not so 
small in relative terms and that our results regarding 
DFI analysis do possess significant statistical power. 
Altogether, a prospective study on a much larger scale 
of patients is needed to validate our conclusions. 
Conclusions 
In summary, our results show that TFF1 expres-
sion is correlated with postmenopausal status, histo-
logical grade of tumor, ER and PR status, which is in 
agreement with the findings of the majority of breast 
cancer studies on TFF1. Distribution of TFF1 levels 
between ER-positive and ER-negative postmenopau-
sal patients bearing tumors of different histological 
grade provided us the basis to establish the cut-off 
value of 14 ng/mg for distinguishing estro-
gen-independent from estrogen-dependent TFF1 ex-
pression in breast cancer. Determination of a biologi-
cally-related cut-off value for TFF1 expression repre-
sents the original contribution of this study to the field 
of breast cancer research. Our results regarding the 
clinical value of TFF1 in breast cancer indicate that 
TFF1 status might be helpful in discriminating pa-
tients at different risk for development of distant me-
tastases within a 3-year follow-up. Within specific 
breast cancer subgroups, TFF1 status might identify 
patients at high risk for relapse (TFF1+ pre II ER+ 
PR+, TFF1+ post II ER+ PR-), as well as those at low 
risk for relapse (TFF1- pre II ER+ PR+, TFF1+ post II 
ER+ PR+) who might not even develop distant me-
tastases during the first 3 years of follow-up. It may be 
assumed that the expression and action of TFF1 in 
breast cancer is regulated via different signaling 
pathways through which it stimulates motility 
and/or proliferation of tumor cells to a different ex-
tent. Further investigations are necessary in order to 
reveal the mechanism of TFF1 action in breast cancer. 
Determination of TFF1 status could assist in making 
decision on administering adjuvant therapy for early 
breast cancer patients during the first 3 years of fol-
low-up.  
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